Boston Scientific Stock Price, News & Analysis (NYSE:BSX)

$27.40 0.15 (0.55 %)
(As of 01/19/2018 10:25 AM ET)
Previous Close$27.25
Today's Range$27.10 - $27.50
52-Week Range$23.29 - $29.93
Volume6.94 million shs
Average Volume10.93 million shs
Market Capitalization$37.42 billion
P/E Ratio44.92
Dividend YieldN/A
Beta0.96

About Boston Scientific (NYSE:BSX)

Boston Scientific logoBoston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

Receive BSX News and Ratings via Email

Sign-up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:BSX
CUSIP10113710
Phone508-683-4000

Debt

Debt-to-Equity Ratio0.58%
Current Ratio0.72%
Quick Ratio0.50%

Price-To-Earnings

Trailing P/E Ratio44.9180327868852
Forward P/E Ratio21.92
P/E Growth1.95

Sales & Book Value

Annual Sales$8.39 billion
Price / Sales4.49
Cash Flow$1.74 per share
Price / Cash15.72
Book Value$4.94 per share
Price / Book5.55

Profitability

Trailing EPS$0.61
Net Income$347 million
Net Margins9.55%
Return on Equity23.60%
Return on Assets9.24%

Miscellaneous

Employees27,000
Outstanding Shares1,373,200,000

Boston Scientific (NYSE:BSX) Frequently Asked Questions

What is Boston Scientific's stock symbol?

Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

How were Boston Scientific's earnings last quarter?

Boston Scientific Corporation (NYSE:BSX) released its quarterly earnings data on Thursday, October, 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.31. The medical equipment provider earned $2.22 billion during the quarter, compared to analyst estimates of $2.21 billion. Boston Scientific had a net margin of 9.55% and a return on equity of 23.60%. Boston Scientific's quarterly revenue was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.27 EPS. View Boston Scientific's Earnings History.

When will Boston Scientific make its next earnings announcement?

Boston Scientific is scheduled to release their next quarterly earnings announcement on Thursday, February, 1st 2018. View Earnings Estimates for Boston Scientific.

What guidance has Boston Scientific issued on next quarter's earnings?

Boston Scientific updated its fourth quarter earnings guidance on Thursday, October, 26th. The company provided earnings per share (EPS) guidance of $0.32-0.35 for the period, compared to the Thomson Reuters consensus estimate of $0.34. The company issued revenue guidance of $2.345-2.375, compared to the consensus revenue estimate of $2.32 billion.

Where is Boston Scientific's stock going? Where will Boston Scientific's stock price be in 2018?

17 brokers have issued 12 month target prices for Boston Scientific's shares. Their predictions range from $27.00 to $35.00. On average, they expect Boston Scientific's share price to reach $30.87 in the next year. View Analyst Ratings for Boston Scientific.

What are Wall Street analysts saying about Boston Scientific stock?

Here are some recent quotes from research analysts about Boston Scientific stock:

  • 1. Canaccord Genuity analysts commented, "We reiterate our BUY rating and $35 year-end target price on shares of BSX. Our key takeaways from our meeting last week with senior management in San Francisco (as well as incremental tidbits we gleaned over the weekend at the North American Neuromodulation Society (NANS) conference in Vegas) support our general hypothesis on the stock: We expect BSX to deliver top- and bottom-line growth rates above the large-cap medical device peer group average over the 2018-2020 timeframe." (1/17/2018)
  • 2. According to Zacks Investment Research, "Despite back-to-back hurricances, Boston Scientific managed to registered solid third-quarter show. An improving foreign exchange scenario has also started to contribute to the company’s overall top line performance. The raised guidance is indicative of this bullish trend to continue through the rest of 2017. The company is leaving no stone unturned to strengthen its core business and invest more in global markets. Among the recent developments, worth mentioning is the acquisition of Apama Medical, in the field of atrial fibrillation. On the flip side, Boston Scientific's unimpressive pacemaker performance within the core CRM continues remains a drag. This apart, based on the recent announcement, we believe further delay in relaunch of the earlier-recalled Lotus range of heart devices is expected to hamper sales in 2018 too. In the past three months, Boston Scientific has been trading below the broader industry." (1/9/2018)
  • 3. Jefferies Group LLC analysts commented, "We are re-establishing estimates, a Buy rating and $14.00 PT for Flex Pharma. Flex is developing FLX-787, an innovative anti-cramp drug in amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT) and multiple sclerosis (MS). We believe CMT , on which we base our PT , has the highest chance of success. We anticipate Ph2 data in 1Q’18 (MS) and 3Q’18 (ALS, CMT). In 2Q’16, Flex launched HOTSHOT , a consumer beverage for exercise- associated muscle cramps that works via the same mechanisms as FLX-787." (9/7/2017)
  • 4. Needham & Company LLC analysts commented, "BSX beat consensus 1Q17 revenue but missed consensus EPS due to expense associated with the Lotus withdrawal. Management raised its revenue guidance but maintained its EPS guidance for 2017. BSX’s organic revenue growth slowed slightly to 9% in 1Q17 from 10% in 4Q16 despite facing a more difficult comp. MedSurg growth accelerated and offset slower Cardiovascular growth as BSX lapped the US Synergy launch. Margins were below expectations with BSX’s gross margin down 170 bps Y/Y and operating margin down 210 bps Y/Y but this was mostly due to the impact of the Lotus withdrawal." (4/27/2017)

Are investors shorting Boston Scientific?

Boston Scientific saw a drop in short interest during the month of December. As of December 15th, there was short interest totalling 11,837,831 shares, a drop of 21.4% from the November 30th total of 15,058,752 shares. Based on an average daily volume of 12,769,810 shares, the short-interest ratio is currently 0.9 days. Approximately 0.9% of the shares of the stock are short sold.

Who are some of Boston Scientific's key competitors?

Who are Boston Scientific's key executives?

Boston Scientific's management team includes the folowing people:

  • Michael F. Mahoney, Chairman of the Board, President, Chief Executive Officer (Age 52)
  • Daniel J. Brennan, Chief Financial Officer, Executive Vice President (Age 51)
  • Supratim Bose, Executive Vice President; President, Asia-Pacific, Middle East and Africa (Age 64)
  • Keith D. Dawkins M.D., Global Chief Medical Officer, Executive Vice President (Age 66)
  • Joseph M. Fitzgerald, Executive Vice President; President - Rhythm Management (Age 53)
  • Edward F. Mackey, Executive Vice President - Operations (Age 54)
  • Ian T. Meredith AM, Executive Vice President, Global Chief Medical Officer (Age 60)
  • Michael P. Phalen, Executive Vice President; President - MedSurg (Age 57)
  • Desiree Ann Ralls-Morrison, Senior Vice President, General Counsel, Corporate Secretary (Age 51)
  • Wendy Carruthers, Senior Vice President - Human Resources (Age 48)

Who owns Boston Scientific stock?

Boston Scientific's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Schwab Charles Investment Management Inc. (0.36%), Bank of Montreal Can (0.20%), Vontobel Asset Management Inc. (0.12%), National Pension Service (0.09%), Atalanta Sosnoff Capital LLC (0.09%) and Gateway Investment Advisers LLC (0.07%). Company insiders that own Boston Scientific stock include Charles J Dockendorff, Daniel J Brennan, David A Pierce, Jeffrey B Mirviss, John Bradley Sorenson, Joseph Michael Fitzgerald, Karen Prange, Keith D Dawkins, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Michael P Phalen, Supratim Bose, Timothy A Pratt, Valley Gold Master Fund L Sun and Wendy Carruthers. View Institutional Ownership Trends for Boston Scientific.

Who sold Boston Scientific stock? Who is selling Boston Scientific stock?

Boston Scientific's stock was sold by a variety of institutional investors in the last quarter, including Gateway Investment Advisers LLC, First American Trust FSB, Exxonmobil Investment Management Inc. TX, Nisa Investment Advisors LLC, Atalanta Sosnoff Capital LLC, Westpac Banking Corp, Oakbrook Investments LLC and Livforsakringsbolaget Skandia Omsesidigt. Company insiders that have sold Boston Scientific company stock in the last year include Daniel J Brennan, David A Pierce, John Bradley Sorenson, Keith D Dawkins, Kevin J Ballinger, Maulik Nanavaty, Michael P Phalen, Supratim Bose, Timothy A Pratt and Wendy Carruthers. View Insider Buying and Selling for Boston Scientific.

Who bought Boston Scientific stock? Who is buying Boston Scientific stock?

Boston Scientific's stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Vontobel Asset Management Inc., Schwab Charles Investment Management Inc., State of Alaska Department of Revenue, Fox Run Management L.L.C., National Pension Service, QUANTRES ASSET MANAGEMENT Ltd and DnB Asset Management AS. Company insiders that have bought Boston Scientific stock in the last two years include Charles J Dockendorff and Valley Gold Master Fund L Sun. View Insider Buying and Selling for Boston Scientific.

How do I buy Boston Scientific stock?

Shares of Boston Scientific can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Boston Scientific's stock price today?

One share of Boston Scientific stock can currently be purchased for approximately $27.40.

How big of a company is Boston Scientific?

Boston Scientific has a market capitalization of $37.42 billion and generates $8.39 billion in revenue each year. The medical equipment provider earns $347 million in net income (profit) each year or $0.61 on an earnings per share basis. Boston Scientific employs 27,000 workers across the globe.

How can I contact Boston Scientific?

Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected]


MarketBeat Community Rating for Boston Scientific (BSX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  586 (Vote Outperform)
Underperform Votes:  539 (Vote Underperform)
Total Votes:  1,125
MarketBeat's community ratings are surveys of what our community members think about Boston Scientific and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Boston Scientific (NYSE:BSX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.822.882.752.71
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
12 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
13 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $30.87$30.90$30.58$29.91
Price Target Upside: 13.27% upside20.66% upside3.90% upside7.65% upside

Boston Scientific (NYSE:BSX) Consensus Price Target History

Price Target History for Boston Scientific (NYSE:BSX)

Boston Scientific (NYSE:BSX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/17/2018Canaccord GenuityReiterated RatingBuyLowView Rating Details
1/16/2018Needham & Company LLCReiterated RatingBuy$32.00LowView Rating Details
1/10/2018BarclaysReiterated RatingBuy$32.00LowView Rating Details
1/5/2018Royal Bank of CanadaUpgradeOutperform -> Top PickMediumView Rating Details
1/3/2018Evercore ISIInitiated CoverageIn -> In-Line$27.00MediumView Rating Details
12/12/2017BMO Capital MarketsReiterated RatingBuy$32.00LowView Rating Details
12/4/2017SunTrust BanksSet Price TargetBuy$33.00LowView Rating Details
11/30/2017CowenSet Price TargetBuy$31.00LowView Rating Details
11/30/2017BTIG ResearchUpgradeNeutral -> Buy$31.00MediumView Rating Details
11/29/2017JPMorgan Chase & Co.Reiterated RatingBuyLowView Rating Details
11/29/2017OppenheimerReiterated RatingHoldHighView Rating Details
9/25/2017Stifel NicolausReiterated RatingBuy$32.00LowView Rating Details
9/7/2017Jefferies GroupReiterated RatingHoldLowView Rating Details
6/16/2017Wells Fargo & CoReiterated RatingOutperform$29.50 -> $31.00LowView Rating Details
5/16/2017Goldman Sachs GroupInitiated CoverageNeutral -> Neutral$28.00LowView Rating Details
4/12/2017GuggenheimReiterated RatingBuyLowView Rating Details
2/23/2017Northland SecuritiesReiterated RatingPositiveN/AView Rating Details
10/6/2016CitigroupBoost Price TargetBuy$28.00 -> $29.00N/AView Rating Details
9/1/2016ArgusUpgradeHold -> Buy$23.82 -> $33.00N/AView Rating Details
7/29/2016Credit Suisse GroupReiterated RatingBuyN/AView Rating Details
7/29/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
7/29/2016WedbushBoost Price TargetNeutral$23.00 -> $25.00N/AView Rating Details
7/28/2016BenchmarkBoost Price TargetBuy$25.00 -> $31.00N/AView Rating Details
6/21/2016Piper Jaffray CompaniesReiterated RatingOverweight$26.00N/AView Rating Details
3/27/2016Morgan StanleyReiterated RatingOverweight$22.00N/AView Rating Details
3/25/2016Bank of AmericaReiterated RatingBuy$23.00N/AView Rating Details
3/18/2016Longbow ResearchInitiated CoverageBuyN/AView Rating Details
3/17/2016NomuraInitiated CoverageBuy$22.00N/AView Rating Details
3/12/2016Deutsche BankReiterated RatingHoldN/AView Rating Details
(Data available from 1/19/2016 forward)

Earnings

Boston Scientific (NYSE:BSX) Earnings History and Estimates Chart

Earnings by Quarter for Boston Scientific (NYSE:BSX)

Boston Scientific (NYSE BSX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/1/2018$0.34N/AView Earnings Details
10/26/2017Q3 2017$0.31$0.31$2.21 billion$2.22 billionViewN/AView Earnings Details
7/27/2017Q2 2017$0.31$0.32$2.21 billion$2.26 billionViewN/AView Earnings Details
4/27/2017Q1 2017$0.30$0.29$2.08 billion$2.16 billionViewN/AView Earnings Details
2/2/2017Q416$0.29$0.30$2.16 billion$2.19 billionViewListenView Earnings Details
10/26/2016Q316$0.27$0.27$2.07 billion$2.11 billionViewListenView Earnings Details
7/28/2016Q216$0.27$0.27$2.05 billion$2.13 billionViewListenView Earnings Details
4/27/2016Q116$0.24$0.28$1.91 billion$1.96 billionViewListenView Earnings Details
2/4/2016Q415$0.25$0.26$2.00 billion$1.98 billionViewListenView Earnings Details
10/28/2015Q315$0.23$0.24$1.86 billion$1.89 billionViewListenView Earnings Details
7/23/2015Q215$0.21$0.22$1.83 billion$1.84 billionViewListenView Earnings Details
4/28/2015Q115$0.21$0.21$1.78 billion$1.77 billionViewListenView Earnings Details
2/4/2015Q414$0.21$0.22$1.91 billion$1.89 billionViewListenView Earnings Details
10/22/2014Q314$0.20$0.20$1.82 billion$1.85 billionViewListenView Earnings Details
7/24/2014Q214$0.20$0.21$1.87 billion$1.87 billionViewListenView Earnings Details
4/29/2014Q114$0.18$0.20$1.80 billion$1.77 billionViewListenView Earnings Details
2/4/2014Q4$0.13$0.21$1.83 billion$1.84 billionViewListenView Earnings Details
10/24/2013Q313$0.09$0.17$1.73 billion$1.74 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.10$0.18$1.78 billion$1.81 billionViewListenView Earnings Details
4/25/2013Q1 2013$0.09$0.16$1.79 billion$1.76 billionViewListenView Earnings Details
1/29/2013Q4 2012$0.11$0.18$1.76 billion$1.82 billionViewListenView Earnings Details
10/18/2012$0.11($0.52)ViewN/AView Earnings Details
7/26/2012$0.08$0.17ViewN/AView Earnings Details
4/19/2012$0.13$0.15ViewN/AView Earnings Details
2/2/2012$0.08$0.07ViewN/AView Earnings Details
10/20/2011$0.09$0.15ViewN/AView Earnings Details
7/28/2011$0.08$0.17ViewN/AView Earnings Details
4/20/2011$0.04$0.01ViewN/AView Earnings Details
2/1/2011$0.09$0.15ViewN/AView Earnings Details
10/19/2010Q3 2010$0.06$0.12ViewN/AView Earnings Details
7/20/2010Q2 2010$0.03$0.06ViewN/AView Earnings Details
4/26/2010Q1 2010$0.08$0.09ViewN/AView Earnings Details
2/10/2010Q4 2009$0.13$0.20ViewN/AView Earnings Details
10/19/2009Q3 2009$0.14$0.12ViewN/AView Earnings Details
7/20/2009Q2 2009$0.13$0.20ViewN/AView Earnings Details
4/20/2009Q1 2009$0.12$0.13ViewN/AView Earnings Details
1/28/2009Q4 2008$0.13$0.12ViewN/AView Earnings Details
10/21/2008Q3 2008$0.11$0.16ViewN/AView Earnings Details
7/21/2008Q2 2008$0.11$0.13ViewN/AView Earnings Details
4/21/2008Q1 2008$0.12$0.17ViewN/AView Earnings Details
2/4/2008Q4 2007$0.10$0.24ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Boston Scientific (NYSE:BSX) Earnings Estimates

2018 EPS Consensus Estimate: $1.41
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.30$0.33$0.31
Q2 20183$0.36$0.37$0.36
Q3 20184$0.33$0.36$0.35
Q4 20183$0.38$0.40$0.39
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Boston Scientific (NYSE:BSX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Boston Scientific (NYSE BSX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.74%
Institutional Ownership Percentage: 90.51%
Insider Trades by Quarter for Boston Scientific (NYSE:BSX)
Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Boston Scientific (NYSE BSX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/29/2018Michael P. PhalenEVPSell15,835$25.25$399,833.75View SEC Filing  
1/11/2018David A PierceSVPSell8,763$27.74$243,085.6224,201View SEC Filing  
1/9/2018David A PierceSVPSell5,152$27.00$139,104.0038,116View SEC Filing  
12/29/2017Michael P PhalenEVPSell15,835$25.25$399,833.75View SEC Filing  
12/1/2017Timothy A PrattEVPSell10,000$26.04$260,400.00154,681View SEC Filing  
12/1/2017Valley Gold Master Fund L SunInsiderBuy27,431$0.44$12,069.64
11/29/2017Michael P. PhalenEVPSell15,500$26.66$413,230.00View SEC Filing  
11/28/2017Valley Gold Master Fund L SunInsiderBuy408,006$0.45$183,602.70
11/1/2017Timothy A PrattEVPSell10,000$28.22$282,200.00164,681View SEC Filing  
10/30/2017Michael P. PhalenEVPSell15,500$28.42$440,510.00View SEC Filing  
10/4/2017Supratim BoseEVPSell347,137$29.12$10,108,629.44View SEC Filing  
10/2/2017Timothy A PrattEVPSell11,061$29.24$323,423.64174,681View SEC Filing  
9/29/2017Michael P. PhalenEVPSell15,500$28.72$445,160.00View SEC Filing  
9/1/2017Timothy A PrattEVPSell10,104$27.46$277,455.84185,742View SEC Filing  
8/31/2017Maulik NanavatySVPSell57,031$27.28$1,555,805.68View SEC Filing  
8/30/2017Maulik NanavatySVPSell27,031$27.08$731,999.48View SEC Filing  
8/29/2017Michael P. PhalenEVPSell15,500$26.87$416,485.00View SEC Filing  
8/3/2017Wendy CarruthersSVPSell12,433$26.75$332,582.75View SEC Filing  
8/2/2017John Bradley SorensonSVPSell7,900$26.37$208,323.0021,680View SEC Filing  
8/1/2017Timothy A PrattEVPSell10,000$26.67$266,700.00195,846View SEC Filing  
7/31/2017John Bradley SorensonSVPSell2,100$27.15$57,015.0018,880View SEC Filing  
7/31/2017Michael P. PhalenEVPSell15,500$27.13$420,515.00View SEC Filing  
7/11/2017Daniel J BrennanCFOSell92,158$27.48$2,532,501.84235,421View SEC Filing  
7/3/2017Timothy A PrattEVPSell10,000$27.87$278,700.00205,846View SEC Filing  
6/29/2017Michael P. PhalenEVPSell15,500$28.02$434,310.00View SEC Filing  
6/9/2017David A PierceSVPSell13,562$28.00$379,736.0033,701View SEC Filing  
6/2/2017David A PierceSVPSell2,972$27.70$82,324.4028,572View SEC Filing  
6/1/2017Timothy A PrattEVPSell10,000$27.13$271,300.00215,846View SEC Filing  
5/30/2017Michael P. PhalenEVPSell15,500$27.25$422,375.00View SEC Filing  
5/17/2017Kevin J. BallingerEVPSell28,864$26.14$754,504.96View SEC Filing  
5/1/2017Timothy A PrattEVPSell10,000$26.37$263,700.00225,846View SEC Filing  
4/26/2017David A PierceSVPSell10,250$26.00$266,500.0035,850View SEC Filing  
4/26/2017Michael P. PhalenEVPSell34,773$26.00$904,098.00View SEC Filing  
4/10/2017John Bradley SorensonSVPSell2,950$24.66$72,747.0020,980View SEC Filing  
4/3/2017Timothy A PrattEVPSell10,000$24.87$248,700.00235,846View SEC Filing  
3/29/2017Michael P. PhalenEVPSell79,045$24.55$1,940,554.75View SEC Filing  
3/3/2017David A PierceSVPSell25,012$25.01$625,550.1225,600View SEC Filing  
3/3/2017Timothy A PrattEVPSell23,540$25.01$588,735.40245,846View SEC Filing  
2/27/2017David A PierceSVPSell3,417$24.84$84,878.2834,267View SEC Filing  
2/27/2017Timothy A PrattEVPSell4,832$24.84$120,026.88248,758View SEC Filing  
2/7/2017Keith D DawkinsEVPSell80,783$25.21$2,036,539.4375,864View SEC Filing  
1/9/2017David A PierceSVPSell10,232$22.24$227,559.6825,600View SEC Filing  
1/9/2017Timothy A PrattEVPSell6,195$22.24$137,776.80231,273View SEC Filing  
12/1/2016Timothy A PrattEVPSell26,726$20.48$547,348.48260,430View SEC Filing  
8/11/2016John Bradley SorensonSVPSell2,500$23.90$59,750.0012,615View SEC Filing  
8/1/2016Michael F MahoneyCEOSell44,400$24.44$1,085,136.001,388,177View SEC Filing  
8/1/2016Timothy A PrattEVPSell24,000$24.46$587,040.00287,495View SEC Filing  
7/20/2016David A PierceSVPSell2,480$24.03$59,594.4028,080View SEC Filing  
7/20/2016Michael P. PhalenEVPSell35,000$24.03$841,050.00View SEC Filing  
6/1/2016Michael F MahoneyCEOSell100,000$22.69$2,269,000.001,532,577View SEC Filing  
6/1/2016Timothy A PrattEVPSell24,229$22.66$549,029.14301,724View SEC Filing  
5/11/2016John Bradley SorensonSVPSell2,800$22.15$62,020.0015,115View SEC Filing  
5/10/2016Keith D DawkinsEVPSell80,000$22.15$1,772,000.00150,227View SEC Filing  
5/6/2016Jeffrey B MirvissSVPSell24,659$21.94$541,018.4671,975View SEC Filing  
5/3/2016Joseph Michael FitzgeraldEVPSell79,960$21.81$1,743,927.6092,020View SEC Filing  
5/2/2016Michael F MahoneyCEOSell100,000$22.12$2,212,000.001,632,577View SEC Filing  
5/2/2016Timothy A PrattEVPSell24,000$21.93$526,320.00308,724View SEC Filing  
4/27/2016Kevin J BallingerSVPSell111,807$21.62$2,417,267.3483,600View SEC Filing  
4/27/2016Timothy A PrattEVPSell39,927$21.40$854,437.80291,724View SEC Filing  
4/4/2016Jeffrey B MirvissSVPSell18,422$19.00$350,018.0096,634View SEC Filing  
4/1/2016Michael F MahoneyCEOSell100,000$18.90$1,890,000.001,732,577View SEC Filing  
4/1/2016Timothy A PrattEVPSell24,000$18.73$449,520.00355,651View SEC Filing  
3/11/2016Kevin J BallingerSVPSell16,705$18.00$300,690.0046,970View SEC Filing  
3/8/2016Karen PrangeSVPSell14,747$17.27$254,680.6938,395View SEC Filing  
3/2/2016Michael P. PhalenEVPSell10,665$17.17$183,118.0589,309View SEC Filing  
3/1/2016Michael F MahoneyCEOSell100,000$16.96$1,696,000.001,832,577View SEC Filing  
3/1/2016Timothy A PrattEVPSell15,068$16.97$255,703.96338,651View SEC Filing  
2/29/2016Kevin J. BallingerSVPSell2,114$17.17$36,297.38View SEC Filing  
2/29/2016Michael P. PhalenEVPSell1,819$17.19$31,268.61View SEC Filing  
2/25/2016Daniel J BrennanCFOSell103,211$17.22$1,777,293.42202,659View SEC Filing  
2/25/2016Kevin J. BallingerSVPSell1,903$17.48$33,264.44View SEC Filing  
2/25/2016Michael P. PhalenEVPSell34,106$17.28$589,351.68View SEC Filing  
2/17/2016Kevin J. BallingerSVPSell7,616$17.37$132,289.92View SEC Filing  
2/12/2016Charles J DockendorffDirectorBuy30,000$16.49$494,700.0041,598View SEC Filing  
2/8/2016Karen PrangeSVPSell6,216$16.05$99,766.8023,647View SEC Filing  
1/8/2016Timothy A PrattEVPSell7,160$17.67$126,517.20303,776View SEC Filing  
1/7/2016Kevin J BallingerSVPSell19,059$17.73$337,916.0730,323View SEC Filing  
1/5/2016Jeffrey B MirvissSVPSell9,953$18.00$179,154.0082,535View SEC Filing  
12/1/2015Timothy A. PrattEVPSell24,000$18.43$442,320.00282,295View SEC Filing  
11/16/2015Ernest MarioDirectorSell125,000$17.63$2,203,750.0086,032View SEC Filing  
11/9/2015John Bradley SorensonSVPSell4,469$18.68$83,480.925,605View SEC Filing  
11/9/2015Joseph Michael FitzgeraldEVPSell26,220$18.58$487,167.60103,925View SEC Filing  
11/5/2015Timothy A PrattEVPSell19,598$19.00$372,362.00289,295View SEC Filing  
10/28/2015Jeffrey B MirvissSVPSell9,492$18.00$170,856.0081,262View SEC Filing  
10/28/2015Timothy A PrattEVPSell3,500$18.00$63,000.00315,893View SEC Filing  
10/5/2015Timothy A PrattEVPSell3,500$17.34$60,690.00319,393View SEC Filing  
10/1/2015Timothy A. PrattEVPSell17,000$16.33$277,610.00322,893View SEC Filing  
8/21/2015John E AbeleDirectorBuy200,000$16.77$3,354,000.0092,983View SEC Filing  
8/19/2015John E AbeleDirectorBuy200,000$17.48$3,496,000.0092,983View SEC Filing  
8/17/2015John E AbeleDirectorBuy100,000$17.50$1,750,000.00View SEC Filing  
7/7/2015Karen PrangeSVPSell17,456$17.66$308,272.96View SEC Filing  
5/29/2015Maulik NanavatySVPSell71,558$18.52$1,325,254.16View SEC Filing  
5/28/2015Wendy CarruthersSVPSell42,281$17.91$757,252.71View SEC Filing  
5/18/2015Ernest MarioDirectorSell50,000$18.09$904,500.00View SEC Filing  
5/14/2015John E SununuDirectorSell10,000$17.87$178,700.00View SEC Filing  
5/11/2015John Bradley SorensonSVPSell8,735$17.49$152,775.15View SEC Filing  
3/20/2015David A PierceSVPSell18,050$18.00$324,900.00View SEC Filing  
3/20/2015Michael P PhalenEVPSell46,085$17.94$826,764.90View SEC Filing  
3/16/2015Michael P PhalenEVPSell30,022$17.18$515,777.96View SEC Filing  
3/13/2015John Bradley SorensonSVPSell3,830$16.84$64,497.20View SEC Filing  
3/9/2015David A PierceSVPSell2,561$16.54$42,358.94View SEC Filing  
3/3/2015David A PierceSVPSell8,983$16.79$150,824.57View SEC Filing  
3/3/2015Michael P PhalenEVPSell12,768$16.79$214,374.72View SEC Filing  
2/27/2015David A PierceSVPSell19,046$16.80$319,972.80View SEC Filing  
2/27/2015Michael P PhalenEVPSell1,819$16.80$30,559.20View SEC Filing  
2/19/2015David A PierceSVPSell11,958$16.46$196,828.68View SEC Filing  
2/19/2015Michael P PhalenEVPSell13,188$16.44$216,810.72View SEC Filing  
2/10/2015Joseph Michael FitzgeraldEVPSell61,208$14.66$897,309.28View SEC Filing  
2/9/2015David A PierceSVPSell5,000$14.66$73,300.00View SEC Filing  
2/6/2015Kevin J BallingerSVPSell21,408$15.06$322,404.48View SEC Filing  
1/20/2015Michael P PhalenEVPSell10,000$14.54$145,400.00View SEC Filing  
1/8/2015David A PierceSVPSell18,612$14.31$266,337.72View SEC Filing  
1/8/2015Michael P PhalenEVPSell27,589$14.31$394,798.59View SEC Filing  
1/5/2015Michael P PhalenEVPSell10,000$13.75$137,500.00View SEC Filing  
12/10/2014Karen PrangeSVPSell19,753$12.64$249,677.92View SEC Filing  
12/8/2014David A PierceSVPSell5,000$12.90$64,500.00View SEC Filing  
12/1/2014Ernest MarioDirectorSell10,000$12.96$129,600.00View SEC Filing  
11/28/2014Michael F MahoneyCEOBuy11,700$12.89$150,813.00View SEC Filing  
11/10/2014Edward J LudwigDirectorBuy10,000$13.38$133,800.00View SEC Filing  
11/5/2014John E SununuDirectorSell8,997$13.38$120,379.86View SEC Filing  
11/3/2014Ernest MarioDirectorSell10,000$13.30$133,000.00View SEC Filing  
10/8/2014Ernest MarioDirectorSell10,000$12.06$120,600.00View SEC Filing  
9/2/2014Ernest MarioDirectorSell10,000$12.60$126,000.00View SEC Filing  
8/15/2014Michael P PhalenEVPSell11,471$12.58$144,305.18View SEC Filing  
8/1/2014Ernest MarioDirectorSell10,000$12.58$125,800.00View SEC Filing  
7/30/2014David A PierceSVPSell157$12.97$2,036.29View SEC Filing  
7/15/2014Michael P PhalenEVPSell67,500$13.04$880,200.00View SEC Filing  
7/1/2014Ernest MarioDirectorSell10,000$12.95$129,500.00View SEC Filing  
6/16/2014Michael P PhalenEVPSell13,500$13.02$175,770.00View SEC Filing  
6/2/2014Ernest MarioDirectorSell10,000$12.88$128,800.00View SEC Filing  
5/15/2014Michael PhalenEVPSell13,500$12.76$172,260.00127,486View SEC Filing  
5/1/2014Ernest MarioDirectorSell10,000$12.58$125,800.00317,855View SEC Filing  
4/15/2014Michael PhalenEVPSell13,500$13.25$178,875.00127,486View SEC Filing  
4/1/2014Ernest MarioDirectorSell10,000$13.55$135,500.00327,855View SEC Filing  
3/17/2014Michael PhalenEVPSell13,500$13.05$176,175.00127,486View SEC Filing  
3/6/2014David PierceSVPSell5,316$13.44$71,447.0443,161View SEC Filing  
3/6/2014Michael PhalenEVPSell7,281$13.44$97,856.64127,486View SEC Filing  
2/27/2014David PierceSVPSell2,057$13.29$27,337.5347,990View SEC Filing  
2/27/2014Michael PhalenEVPSell3,166$13.29$42,076.14130,848View SEC Filing  
2/21/2014David PierceSVPSell3,199$13.22$42,290.7825,600View SEC Filing  
2/21/2014Michael PhalenEVPSell3,222$13.22$42,594.8484,300View SEC Filing  
2/18/2014Michael PhalenEVPSell13,500$13.30$179,550.0087,522View SEC Filing  
2/13/2014Kristina JohnsonDirectorSell18,000$13.01$234,180.003,124View SEC Filing  
2/6/2014Ernest MarioDirectorSell17,104$12.80$218,931.20347,855View SEC Filing  
2/3/2014Ernest MarioDirectorSell10,000$13.19$131,900.00364,959View SEC Filing  
1/6/2014Ernest MarioDirectorSell10,000$12.50$125,000.00374,959View SEC Filing  
12/26/2013Ernest MarioDirectorSell10,000$12.06$120,600.00384,959View SEC Filing  
11/26/2013Jeffrey CapelloCFOSell85,106$11.82$1,005,952.92109,042View SEC Filing  
11/11/2013Jeffrey MirvissSVPSell26,000$11.91$309,660.0039,190View SEC Filing  
8/29/2013Jeffrey CapelloCFOSell525,000$10.68$5,607,000.00147,447View SEC Filing  
8/16/2013Joseph Michael FitzgeraldSVPSell9,202$11.02$101,406.0493,191View SEC Filing  
8/14/2013Kevin BallingerSVPSell38,171$11.28$430,568.8873,519View SEC Filing  
5/31/2013Jeffrey B MirvissSVPSell10,941$9.37$102,517.17View SEC Filing  
5/30/2013Wendy CarruthersSVPSell25,001$9.16$229,009.16View SEC Filing  
5/29/2013Nelda J ConnorsDirectorSell24,116$9.17$221,143.72View SEC Filing  
5/6/2013Ernest MarioDirectorBuy30,000$7.76$232,800.00View SEC Filing  
11/13/2012Nj Nicholas JrDirectorBuy20,000$5.28$105,600.00View SEC Filing  
11/9/2012Nj Nicholas JrDirectorBuy25,000$5.17$129,250.00View SEC Filing  
8/6/2012Ernest MarioDirectorBuy32,000$5.29$169,280.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Boston Scientific (NYSE BSX) News Headlines

Source:
DateHeadline
Boston Scientific (BSX) Stock Rating Reaffirmed by Canaccord GenuityBoston Scientific (BSX) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - January 17 at 8:28 PM
Boston Scientifics Positive SCS Trial Aids NeuromodulationBoston Scientific's Positive SCS Trial Aids Neuromodulation
www.zacks.com - January 16 at 9:51 AM
Boston Scientific's Positive SCS Trial Aids NeuromodulationBoston Scientific's Positive SCS Trial Aids Neuromodulation
finance.yahoo.com - January 16 at 9:51 AM
Boston Scientific (BSX) Reports Positive Results from WHISPER Spinal Cord Stimulation StudyBoston Scientific (BSX) Reports Positive Results from WHISPER Spinal Cord Stimulation Study
www.streetinsider.com - January 13 at 9:44 AM
Boston Scientific (BSX) Reports FDA Approval for Spectra WaveWriter Spinal Cord StimulatorBoston Scientific (BSX) Reports FDA Approval for Spectra WaveWriter Spinal Cord Stimulator
www.streetinsider.com - January 12 at 4:53 PM
Boston Scientific Announces Positive Results from WHISPER Spinal Cord Stimulation StudyBoston Scientific Announces Positive Results from WHISPER Spinal Cord Stimulation Study
finance.yahoo.com - January 12 at 4:53 PM
MedTech Tax Resumes in 2018, 3 Stocks to SufferMedTech Tax Resumes in 2018, 3 Stocks to Suffer
finance.yahoo.com - January 12 at 9:53 AM
Why Mizuho Securities Upgraded Teva Pharmaceutical to a ‘Buy’Why Mizuho Securities Upgraded Teva Pharmaceutical to a ‘Buy’
finance.yahoo.com - January 12 at 9:53 AM
Boston Scientific Corporation (BSX) SVP David A. Pierce Sells 8,763 SharesBoston Scientific Corporation (BSX) SVP David A. Pierce Sells 8,763 Shares
www.americanbankingnews.com - January 11 at 6:58 PM
Boston Scientific scores FDA nod for personalized pain deviceBoston Scientific scores FDA nod for personalized pain device
finance.yahoo.com - January 11 at 5:10 PM
Boston Scientific: Pain Management Without The PillsBoston Scientific: Pain Management Without The Pills
www.nasdaq.com - January 11 at 10:09 AM
Boston Scientific Receives U.S. FDA Approval for Spectra WaveWriter™ Spinal Cord Stimulator SystemBoston Scientific Receives U.S. FDA Approval for Spectra WaveWriter™ Spinal Cord Stimulator System
finance.yahoo.com - January 11 at 10:09 AM
David A. Pierce Sells 5,152 Shares of Boston Scientific Corporation (BSX) StockDavid A. Pierce Sells 5,152 Shares of Boston Scientific Corporation (BSX) Stock
www.americanbankingnews.com - January 10 at 8:00 PM
Boston Scientific Rises 8.3% on Upbeat 4Q Preliminary SalesBoston Scientific Rises 8.3% on Upbeat 4Q Preliminary Sales
finance.yahoo.com - January 10 at 5:00 PM
Boston Scientific (BSX) Receives Buy Rating from BarclaysBoston Scientific (BSX) Receives Buy Rating from Barclays
www.americanbankingnews.com - January 10 at 12:50 PM
Boston Scientific (BSX) Prelim. Q4 Sales Top ViewsBoston Scientific (BSX) Prelim. Q4 Sales Top Views
www.streetinsider.com - January 10 at 9:55 AM
Boston Scientific (BSX) Shares Cross Above 200 DMABoston Scientific (BSX) Shares Cross Above 200 DMA
www.nasdaq.com - January 9 at 5:06 PM
Boston Scientific gets $2B market cap bump as early sales figures impressBoston Scientific gets $2B market cap bump as early sales figures impress
finance.yahoo.com - January 9 at 5:06 PM
What does Boston Scientific Corporation’s (NYSE:BSX) Balance Sheet Tell Us Abouts Its Future?What does Boston Scientific Corporation’s (NYSE:BSX) Balance Sheet Tell Us Abouts Its Future?
finance.yahoo.com - January 9 at 5:06 PM
Wall Street Shows Confidence in BAX StockWall Street Shows Confidence in BAX Stock
finance.yahoo.com - January 9 at 5:06 PM
Baxter International’s Profit Margins Expected to ExpandBaxter International’s Profit Margins Expected to Expand
finance.yahoo.com - January 9 at 5:06 PM
The Hot Stock: Boston Scientific Pops 8.3%The Hot Stock: Boston Scientific Pops 8.3%
finance.yahoo.com - January 9 at 5:06 PM
Boston Scientific Q4 Preliminary Sales Up 9.9%Boston Scientific Q4 Preliminary Sales Up 9.9%
www.nasdaq.com - January 9 at 9:48 AM
Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year Ended December 31, 2017Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year Ended December 31, 2017
www.prnewswire.com - January 9 at 6:55 AM
Boston Scientific Corporation (BSX) Expected to Announce Quarterly Sales of $2.35 BillionBoston Scientific Corporation (BSX) Expected to Announce Quarterly Sales of $2.35 Billion
www.americanbankingnews.com - January 9 at 2:58 AM
Zacks: Analysts Anticipate Boston Scientific Corporation (BSX) to Announce $0.34 EPSZacks: Analysts Anticipate Boston Scientific Corporation (BSX) to Announce $0.34 EPS
www.americanbankingnews.com - January 7 at 9:32 PM
Boston Scientific (BSX) Upgraded at Royal Bank of CanadaBoston Scientific (BSX) Upgraded at Royal Bank of Canada
www.americanbankingnews.com - January 7 at 12:44 AM
Boston Scientific Corporation (BSX) EVP Sells $399,833.75 in StockBoston Scientific Corporation (BSX) EVP Sells $399,833.75 in Stock
www.americanbankingnews.com - January 3 at 9:26 PM
Insider Selling: Boston Scientific Corporation (BSX) EVP Sells 15,835 Shares of StockInsider Selling: Boston Scientific Corporation (BSX) EVP Sells 15,835 Shares of Stock
www.americanbankingnews.com - January 3 at 9:26 PM
Boston Scientific to Webcast Conference Call Discussing Fourth Quarter 2017 Financial ResultsBoston Scientific to Webcast Conference Call Discussing Fourth Quarter 2017 Financial Results
finance.yahoo.com - January 3 at 9:07 AM
Short Interest in Boston Scientific Corporation (BSX) Decreases By 21.4%Short Interest in Boston Scientific Corporation (BSX) Decreases By 21.4%
www.americanbankingnews.com - January 3 at 4:06 AM
Comparing Luna Innovations (LUNA) & Boston Scientific (BSX)Comparing Luna Innovations (LUNA) & Boston Scientific (BSX)
www.americanbankingnews.com - December 26 at 11:30 AM
 Analysts Anticipate Boston Scientific Corporation (BSX) to Announce $0.34 EPS Analysts Anticipate Boston Scientific Corporation (BSX) to Announce $0.34 EPS
www.americanbankingnews.com - December 22 at 1:20 PM
Boston Scientific’s Latest Valuation MetricsBoston Scientific’s Latest Valuation Metrics
finance.yahoo.com - December 21 at 5:04 PM
ETFs with exposure to Boston Scientific Corp. : December 20, 2017ETFs with exposure to Boston Scientific Corp. : December 20, 2017
finance.yahoo.com - December 20 at 5:01 PM
Boston Scientific: What’s behind Needham’s Recent Upgrade?Boston Scientific: What’s behind Needham’s Recent Upgrade?
finance.yahoo.com - December 20 at 5:01 PM
Analyst Ratings for Boston Scientific: Mostly ‘Strong Buy’Analyst Ratings for Boston Scientific: Mostly ‘Strong Buy’
finance.yahoo.com - December 20 at 5:01 PM
Financial Contrast: Boston Scientific (BSX) versus Dynatronics (DYNT)Financial Contrast: Boston Scientific (BSX) versus Dynatronics (DYNT)
www.americanbankingnews.com - December 19 at 9:32 AM
Will Heart Valve Delay Impact Boston Scientific?Will Heart Valve Delay Impact Boston Scientific?
finance.yahoo.com - December 14 at 5:34 PM
Boston Scientific (BSX) Receives Buy Rating from BMO Capital MarketsBoston Scientific (BSX) Receives Buy Rating from BMO Capital Markets
www.americanbankingnews.com - December 12 at 8:38 PM
Earnings Growth Keep Boston Scientific (BSX) a BuyEarnings Growth Keep Boston Scientific (BSX) a Buy
investorplace.com - December 12 at 12:00 PM
Boston Scientific Stock Up As FDA OKs Vercise Deep Brain Stimulation SystemBoston Scientific Stock Up As FDA OKs Vercise Deep Brain Stimulation System
www.nasdaq.com - December 12 at 10:15 AM
Boston Scientific shares rise on U.S. approval for Parkinson’s disease treatmentBoston Scientific shares rise on U.S. approval for Parkinson’s disease treatment
finance.yahoo.com - December 12 at 10:15 AM
Boston Scientific Receives U.S. FDA Approval for the Vercise™ Deep Brain Stimulation SystemBoston Scientific Receives U.S. FDA Approval for the Vercise™ Deep Brain Stimulation System
finance.yahoo.com - December 11 at 5:14 PM
Financial Comparison: Boston Scientific (BSX) versus Viveve Medical (VIVE)Financial Comparison: Boston Scientific (BSX) versus Viveve Medical (VIVE)
www.americanbankingnews.com - December 9 at 6:24 PM
6 Reasons Why Needham Upgraded Boston Scientific6 Reasons Why Needham Upgraded Boston Scientific
finance.yahoo.com - December 9 at 9:50 AM
Boston Scientific (BSX) Rating Lowered to C+ at TheStreetBoston Scientific (BSX) Rating Lowered to C+ at TheStreet
www.americanbankingnews.com - December 9 at 9:22 AM
Boston Scientific (BSX) Lifted to Strong-Buy at Needham & Company LLCBoston Scientific (BSX) Lifted to Strong-Buy at Needham & Company LLC
www.americanbankingnews.com - December 8 at 11:12 PM
6 Reasons Why Needham Upgraded Boston Scientific - Benzinga6 Reasons Why Needham Upgraded Boston Scientific - Benzinga
www.benzinga.com - December 8 at 4:57 PM
$2.35 Billion in Sales Expected for Boston Scientific Corporation (BSX) This Quarter$2.35 Billion in Sales Expected for Boston Scientific Corporation (BSX) This Quarter
www.americanbankingnews.com - December 6 at 5:00 AM

SEC Filings

Boston Scientific (NYSE:BSX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Boston Scientific (NYSE:BSX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Boston Scientific (NYSE BSX) Stock Chart for Friday, January, 19, 2018

Loading chart…

This page was last updated on 1/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.